GERO - Physics and AI Technology Platform for Age-Related Diseases
Stage
Early-stage discovery research
Area
Drug discovery
Status
Ongoing
Patent Status
Multiple patent applications pending
Background
Human aging, a complex phenomenon, has intrigued scientists for generations. GERO, at the forefront of this research, offers a fresh lens to understand and combat aging. Through innovative methods, they've identified two distinct aging phenotypes: Frailty (Late-life phenotype) and True Aging (Whole-life phenotype). Their unique platform unravels the intricacies of aging, presenting a simplified and actionable blueprint for interventions, thereby addressing numerous age-associated conditions in tandem.
Aims, Hypothesis & Results
GERO's primary objective is to radically decelerate human aging. Rooted in the physics of complex systems and real-world human data, they hypothesize that aging is an irreversible, entropy-driven process, but its speed can be modulated. Their focus is on pinpointing druggable sources of this entropic damage to develop effective therapeutics. Through their unique approach, GERO has identified genetic pathways to target multiple diseases simultaneously. Preliminary tests, like their work on immuno-senolytic assets, have demonstrated marked improvements in lifespan and a decrease in senescence markers in older mice.
Timeline
GERO seek to validate their platform through in vivo experiments with Pfizer and aim for extended collaboration.
Additionally, they are currently negotiating with another top-5 pharma company to secure an additional deal.
Later on, GERO are looking to achieve in vivo proof that the True Aging phenotype can be both measured and altered through intervention.
Finally, they want to raise over $30M in their upcoming financing round to advance pipeline assets targeting significant deceleration of human aging.
Financing Round
Required Funding: $30M+
VitaDAO Board Evaluation Write-up
GERO, leveraging collaborations like the one with Pfizer, harnesses AI for innovative drug discovery, offering streamlined processes and the potential for diverse therapeutic applications. Positioned to be a leader in the global longevity market, GERO's adaptable platform and strategic partnerships promise a bright future in the rapidly advancing and increasingly competitive intersection of AI and biopharmaceuticals.
Latest Project Updates
Gero’s lead compound has demonstrated strong translational potential with confirmed blood-brain barrier (BBB) penetration and oral bioavailability—two critical properties for CNS drug development. The compound was evaluated in a lipopolysaccharide (LPS)-induced neuroinflammation model, a widely used preclinical system that mirrors key aspects of human neurological and neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and multiple sclerosis.
This latest validation builds on Gero’s prior in vivo work, where the same class of metabolic inhibitors showed therapeutic benefit in models of acute ischemic stroke and Batten disease—a rare pediatric neurodegenerative disorder.
Discover more projects & initiatives
The Longevity Prize
The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.
The VitaDAO Longevity Fellowship
The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.
The Longevity Decentralized Review (TLDR)
The Longevity Decentralized Review (TLDR) is an on-demand service that provides peer reviews of scientific manuscripts and compensates reviewers for their work. It is funded from fees of those who submit their research to be reviewed, as well as donations. The focus of the content is longevity research posted to preprint servers such as Biorxiv, Medrxiv, and Arxiv.
The Longevist - Overlay Longevity Research Journal
An overlay journal to curate the most impactful longevity research every quarter, as voted by a mix of industry & academic experts in the longevity space.
